Global Mastitis Market to Develop at An Optimistic 15.07% CAGR by Forecast Period 2017 to 2023

Overview:

The Global Mastitis Market is expected to reach over 18,338 Million USD by 2023, growing at approximately 15.07% CAGR during the forecast period (2017-2023). In the year 2017, the market had valued at USD 7,898.05 Million.

Mastitis refers to a kind of infection occurring in the tissues of mammary glands in the breast. The mastitis usually affects women who are breastfeeding as a result of a blocked duct. In cows, mastitis occurs as a result of chemical, mechanical, or thermal injury to the cow's udder.

Affected bovine and human population are driving the growth of the global mastitis market. With the various technological advancements in recent years, the global mastitis market has been witnessing many innovations in treatment methods and drugs to treat the infection.

Furthermore, factors such as the growing prevalence of breast cancer is impacting the market growth positively.  Women affected with breast cancer are at high-risk of contracting mastitis during the breastfeeding period. Hence, the rise in the breast cancer cases across the globe accounts for the key risk factor increasing the incidents of the mastitis. 

Rapid changes in lifestyle, eating habits, and changes in the social system over the last few years have been accelerating the market growth. According to the World Cancer Research Fund, breast cancer is the most common cancer in women worldwide and the second most common cancer. The World Cancer Research Fund has also reported over 2 million new cases of breast cancer in 2018.

However, lack of awareness towards the mastitis conditions, low awareness levels regarding bovine health, and the lack of awareness of losses caused by bovine mastitis are some of the factors hampering the market growth. Consequences in incorrect diagnosis due to similarities in the symptoms of breast cancer and mastitis can hamper the market growth.

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/mastitis-market-5379

Segmentation:

The global mastitis market can be segmented by type, treatment, end-user, and region.

On the basis of type, the global mastitis market is segmented into human mastitis and bovine mastitis. The segment bovine mastitis accounted for the major share in the global mastitis market in 2017. Whereas the subsegment contagious mastitis had valued at USD 3,843.23 MN in 2017 and is expected to exhibit a CAGR of 16.91 % during the forecast period (2017-2023). Environmental mastitis accounted for a 38 % of the share of bovine mastitis, in 2017.

On the basis of treatment, the mastitis market is segmented into antibiotics, pain relievers, surgery, vaccines, and others. Antibiotics by bovine treatment accounted for the valuation of USD 6,448.56 million in 2017. The antibiotics subsegment is further expected to register a CAGR of 16.56% throughout the forecast period.

On the basis of end-user, the mastitis market is segmented into hospitals, clinics, veterinary centers, and others. In 2018, the hospitals and clinics segment is expected to account for the largest share of the global mastitis market. Veterinary centers accounted for the largest share of the market in 2017.

The subsegment Veterinary centers by the end-user accounted for the valuation of approximately USD 6,326.34 million in 2017 and is projected to register a CAGR of 16.87% over the forecast period.

Competitive Dashboard:

Prominent players operating in the mastitis market include Bayer AG (Germany), Pfizer Inc. (U.S.), BioNumerik Pharmaceuticals Inc. (U.S.), Zoetis Inc. (U.S.), Sanofi S.A. (France), Merck Co & Inc. (U.S.), Oncothyreon Inc. (U.S.), Oncogenex (U.S.), Apthera Inc. (U.K.), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Boehringer Ingelheim GmbH (Germany), F. Hoffmann-La Roche Ltd. (Switzerland).

Strategic initiatives employed often involve mergers, acquisitions, product launches, and others. These tactical moves ensure individual growth of companies alongside the market’s expansion.

Regional Analysis

The Americas region dominates the global mastitis market mainly due to the higher health care expenditures and the increasing prevalence of mastitis among the bovine population. The US backed by the growing prevalence of human mastitis, and bovine’s mastitis accounts for the major growth supporter to the regional market. The mastitis market in North America is expected to reach USD 7,054.58 Mn by 2023.

Europe mastitis market stands the second position, globally mainly due to the high prevalence of breast cancer. Moreover, factors such as the accessibility to advanced treatment facilities, rising government initiatives to promote healthy breastfeeding, and growing healthcare expenditures are fostering the growth of the regional market.  The European mastitis market is expected to worth USD 5,275.18 Mn by 2023.

The mastitis market in the Asia Pacific region is expected to emerge as a promising market, growing rapidly due to the government initiatives of healthcare reforms. Increasing demand for advanced treatment therapies mainly in emerging economies such as China and India are leading the growth in the mastitis market in the region. The mastitis market in the APAC will reach the valuation of USD 5,000.41 Mn by 2023.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com .